Equinor ASA
CORRECTION - The below stockmarket announcement (SMA) is a correction of the SMA published on 10 February 2021. The reason for correction is linked to update of ex-date on New York Stock Exchange (NYSE) for holders of ADRs.
Key information relating to the proposed cash dividend to be paid by Equinor (OSE: EQNR, NYSE: EQNR) for fourth quarter 2020.
Dividend amount: 0.12
Declared currency: USD
Last day including rights: 11 May 2021
Ex-date Oslo Børs (Oslo Stock Exchange): 12 May 2021
Ex-date NYSE: 13 May 2021
Record date: 14 May 2021
Payment date: 27 May 2021
The proposed dividend amount is subject to approval by the Annual General Meeting on 11 May 2021.
Other information: Dividend per share in NOK will be communicated 19 May 2021.
This information is published in accordance with the requirements of the Continuing Obligations.
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Robex Resources Inc.18.9.2025 08:01:56 CEST | Press release
Robex Announces Acceleration of Warrant Expiry Date
ONWARD Medical NV18.9.2025 07:30:00 CEST | Press release
Concurrent Publications in Nature and Nature Medicine Highlight Advances in Blood Pressure Regulation after Spinal Cord Injury Using ONWARD ARC-IM Therapy
Sampo plc18.9.2025 07:30:00 CEST | Press release
Sampo plc’s share buybacks 17 September 2025
Biotalys NV18.9.2025 07:00:00 CEST | Press release
Biotalys Reports Half-Year 2025 Financial Results and Business Highlights
F. Hoffmann-La Roche Ltd18.9.2025 07:00:00 CEST | Press release
Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom